A One-Strength Dose Escalation Regimen for Birch Pollen SCIT Is Safe and Tolerable in Children, Adolescents, and Adults - PubMed
4 hours ago
- #safety study
- #allergen immunotherapy
- #birch pollen
- A One-Strength dose escalation regimen for birch pollen SCIT is safe and tolerable in patients aged 5-65 years.
- The study compared an accelerated dose escalation schedule (One-Strength group) with the standard regimen (Standard group).
- 201 patients were randomized: 87 adults, 52 adolescents, and 62 children.
- 40.5% of patients experienced treatment-related adverse drug reactions (ADRs), with a higher proportion in the One-Strength group (48.5%) compared to the Standard group (32.0%).
- Most ADRs were local (93.3%) and mild (95.8%).
- Only 4 patients developed systemic ADRs, all classified as WAO grade 1 or 2, with no serious ADRs reported.
- Tolerability was rated as 'very good' or 'good' by over 96% of investigators and patients.
- Safety and tolerability were comparable across all age groups (children, adolescents, and adults).